Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma

Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma

There is an urgent need to develop treatments for patients with melanoma who are refractory to or ineligible for immune checkpoint blockade, including patients who lack BRAF-V600E/K mutations. This is often the case in patients diagnosed with rare melanoma subtypes such as mucosal and acral melanoma...

Full description

Bibliographic Details
Main Authors: Nabanita Mukherjee, Carol M. Amato, Jenette Skees, Kaleb J. Todd, Karoline A. Lambert, William A. Robinson, Robert Van Gulick, Ryan M. Weight, Chiara R. Dart, Richard P. Tobin, Martin D. McCarter, Mayumi Fujita, David A. Norris, Yiqun G. Shellman
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Cancers
Subjects:
melanoma
BRAF-mutant
BRAF-WT
BH3 mimetics
venetoclax
Online Access:https://www.mdpi.com/2072-6694/12/8/2182

Internet

https://www.mdpi.com/2072-6694/12/8/2182

Similar Items